COGSTATE LIMITED (CGS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CGS

CGS - COGSTATE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.03
Index: ALL-ORDS | ALL-TECH

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.23

09 Apr
2026

-0.170

OPEN

$2.42

-7.08%

HIGH

$2.45

241,024

LOW

$2.22

TARGET
$3.20 43.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CGS: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 9.3 xxx
DPS (cps) 3.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 24.6 xxx
Dividend Yield 1.3% xxx
Div Pay Ratio(%) 32.3% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.35%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.87

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx9.2
DPS All xxxxxxxxxxxxxxx2.0
Sales/Revenue xxxxxxxxxxxxxxx82.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.3
Net Operating Cash Flow xxxxxxxxxxxxxxx19.0 M
Net Profit Margin xxxxxxxxxxxxxxx19.11 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx23.32 %
Return on Invested Capital xxxxxxxxxxxxxxx23.11 %
Return on Assets xxxxxxxxxxxxxxx16.89 %
Return on Equity xxxxxxxxxxxxxxx23.32 %
Return on Total Capital xxxxxxxxxxxxxxx29.86 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx18.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx54 M
Price To Book Value xxxxxxxxxxxxxxx4.03

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx4.7 M
Capex % of Sales xxxxxxxxxxxxxxx5.79 %
Cost of Goods Sold xxxxxxxxxxxxxxx51 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

09/04/2026

1

Buy

$3.20

43.50%

Cogstate has reported new third quarter contract sales of $25.4m, ahead of each of the two prior quarters and lifting sales for the year to date to $67.1m.

Bell Potter suspects sales momentum has benefited from diversifying beyond Alzheimer's indications and increased opportunities through channel partners.

Another item that stood out for the broker was FY27 contracted revenue, currently at $35.6m. Revenue estimates are increased for FY27 and FY28 by 3% and 5%, respectively. A Buy rating is maintained. Target is lifted to $3.20 from $2.90.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 3.01 cents and EPS of 9.34 cents.
Bell Potter forecasts a full year FY27 dividend of 3.77 cents and EPS of 12.20 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

09/04/2026

1

Buy

$3.15

41.26%

Canaccord Genuity maintains a Buy rating on Cogstate with $3.15 price target following a third quarter FY26 trading update.

Total sales orders and contracted revenue for FY26 are tracking in line with full-year forecasts, supporting earnings visibility.

The broker highlights expanding opportunities beyond Alzheimer’s into mood, sleep and rare diseases, which are contributing an increasing share of sales.

Earnings leverage is expected over the forecast period, with future valuation supported by continued growth across the pipeline.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 3.01 cents and EPS of 10.55 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 4.52 cents and EPS of 12.05 cents.
Access Extra Coverage Research History >

CGS STOCK CHART

FNArena News on CGS

1
Australian Broker Call *Extra* Edition – Apr 09, 2026

Apr 09 2026 - Daily Market Reports
2
Rudi’s View: Top Picks & Conviction Buys

Mar 19 2026 - Rudi's View
3
Australian Broker Call *Extra* Edition – Feb 25, 2026

Feb 25 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Feb 23, 2026

Feb 23 2026 - Daily Market Reports
5
FNArena Corporate Results Monitor – 20-02-2026

Feb 20 2026 - Australia

Latest Medical Equipment & Devices News

1
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
2
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
3
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
4
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
5
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
6
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
7
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
8
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
9
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
10
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia